ES2963112T3 - Compuestos de imidazoquinolina y usos de los mismos - Google Patents
Compuestos de imidazoquinolina y usos de los mismos Download PDFInfo
- Publication number
- ES2963112T3 ES2963112T3 ES19858183T ES19858183T ES2963112T3 ES 2963112 T3 ES2963112 T3 ES 2963112T3 ES 19858183 T ES19858183 T ES 19858183T ES 19858183 T ES19858183 T ES 19858183T ES 2963112 T3 ES2963112 T3 ES 2963112T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- cancer
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728556P | 2018-09-07 | 2018-09-07 | |
| PCT/US2019/049784 WO2020051356A1 (en) | 2018-09-07 | 2019-09-05 | Imidazoquinoline compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2963112T3 true ES2963112T3 (es) | 2024-03-25 |
Family
ID=69722888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19858183T Active ES2963112T3 (es) | 2018-09-07 | 2019-09-05 | Compuestos de imidazoquinolina y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210214354A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4306523A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022501327A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210074290A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164460A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019335366A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3111786A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2963112T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020051356A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| FI3641771T3 (fi) | 2017-06-23 | 2026-08-11 | Birdie Biopharmaceuticals Inc | Farmaseuttisia koostumuksia |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| BR112022008039A2 (pt) * | 2019-10-29 | 2022-07-12 | Prime Reach Trading Ltd | Compostos de 4-amino-imidazoquinolina e usos relacionados |
| AU2021305193A1 (en) * | 2020-07-08 | 2023-02-09 | Purdue Research Foundation | Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US689338A (en) * | 1901-03-29 | 1901-12-17 | Nat Faucet Company | Tapping-bung. |
| US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP1667694B1 (en) * | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| AU2005284835A1 (en) * | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| US8728486B2 (en) * | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| US9034336B2 (en) * | 2011-08-30 | 2015-05-19 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| ES2804101T3 (es) * | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
| DK4001311T3 (da) * | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546230A (zh) * | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| CN106943598A (zh) * | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
-
2019
- 2019-09-05 EP EP23188546.8A patent/EP4306523A3/en not_active Withdrawn
- 2019-09-05 AU AU2019335366A patent/AU2019335366A1/en not_active Abandoned
- 2019-09-05 EP EP19858183.7A patent/EP3846807B1/en active Active
- 2019-09-05 ES ES19858183T patent/ES2963112T3/es active Active
- 2019-09-05 KR KR1020217010120A patent/KR20210074290A/ko not_active Ceased
- 2019-09-05 CA CA3111786A patent/CA3111786A1/en active Pending
- 2019-09-05 US US17/274,136 patent/US20210214354A1/en not_active Abandoned
- 2019-09-05 JP JP2021512742A patent/JP2022501327A/ja active Pending
- 2019-09-05 CN CN201980068724.0A patent/CN113164460A/zh active Pending
- 2019-09-05 WO PCT/US2019/049784 patent/WO2020051356A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20210214354A1 (en) | 2021-07-15 |
| AU2019335366A1 (en) | 2021-03-25 |
| KR20210074290A (ko) | 2021-06-21 |
| CN113164460A (zh) | 2021-07-23 |
| CA3111786A1 (en) | 2020-03-12 |
| EP3846807A4 (en) | 2022-05-18 |
| JP2022501327A (ja) | 2022-01-06 |
| EP4306523A2 (en) | 2024-01-17 |
| EP3846807A1 (en) | 2021-07-14 |
| WO2020051356A1 (en) | 2020-03-12 |
| EP3846807B1 (en) | 2023-08-02 |
| EP4306523A3 (en) | 2024-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3846807B1 (en) | Imidazoquinoline compounds and uses thereof | |
| ES2858753T3 (es) | Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer | |
| ES3030010T3 (en) | Heterocyclic compounds as immunomodulators | |
| ES2943028T3 (es) | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de PD-L1 | |
| ES2716811T3 (es) | Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas | |
| US10125133B2 (en) | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors | |
| ES2940611T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| ES2804101T3 (es) | Compuestos de 4-amino-imidazoquinolina | |
| TWI652269B (zh) | 氮雜吡啶酮化合物及其用途 | |
| ES2949660T3 (es) | Procedimiento para la preparación de compuestos útiles para tratar la atrofia muscular espinal | |
| ES2578735T3 (es) | Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística | |
| JP2022105091A (ja) | cGASアンタゴニスト化合物 | |
| ES2707885T3 (es) | Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades | |
| ES2935012T3 (es) | Compuesto de difenilaminopirimidina y triazina, y composición farmacéutica y uso del mismo | |
| ES3028360T3 (en) | Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof | |
| US20220251097A1 (en) | Molecules and methods related to treatment of uncontrolled cellular proliferation | |
| US20190343814A1 (en) | Pyrazolopyridine compounds and uses thereof | |
| KR20160128416A (ko) | 아미드 화합물, 그의 제조방법, 및 rna 함유 및/또는 dna 함유 바이러스에 의해 유발된 질환, 및 동반 질환의 예방 및 치료제로서의 용도 | |
| WO2022111636A1 (zh) | 稠合三环化合物、其制备方法及其在医药上的应用 | |
| WO2022022489A1 (zh) | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 | |
| ES2743183T3 (es) | Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras | |
| ES2963696T3 (es) | Compuestos diméricos de indol sustituidos | |
| ES2734364T3 (es) | Agente preventivo y/o terapéutico para enfermedades inmunitarias | |
| ES2334747B2 (es) | Nuevas (rs)- 7- o 9- (1,2,3,5- tetrahidro-4,1-benzocazepin-3-il)-7h o9h-purinas con actividad antitumoral. | |
| HK40101420A (en) | Imidazoquinoline compounds and uses thereof |